Chimerix, Inc.

NasdaqGM:CMRX 주식 보고서

시가총액: US$81.3m

Chimerix 관리

관리 기준 확인 2/4

Chimerix CEO는 Mike Andriole, Aug2023 에 임명되었습니다 의 임기는 1.25 년입니다. 총 연간 보상은 $ 1.31M, 40.3% 로 구성됩니다. 40.3% 급여 및 59.7% 보너스(회사 주식 및 옵션 포함). 는 $ 303.62K 가치에 해당하는 회사 주식의 0.37% 직접 소유합니다. 303.62K. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 5.6 년입니다.

주요 정보

Mike Andriole

최고 경영자

US$1.3m

총 보상

CEO 급여 비율40.3%
CEO 임기1.3yrs
CEO 소유권0.4%
경영진 평균 재임 기간1.2yrs
이사회 평균 재임 기간5.6yrs

최근 관리 업데이트

Recent updates

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Jul 16
We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Jul 20
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Jun 06

Chimerix: Searching For Clarity

Jan 05

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Dec 24
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Sep 16
Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Jun 08
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Jun 04

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

May 13
Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

May 08

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01
Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05
Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

CEO 보상 분석

Mike Andriole 의 보수는 Chimerix 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$85m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$1mUS$528k

-US$82m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

US$180m

Mar 31 2023n/an/a

US$176m

Dec 31 2022US$2mUS$455k

US$172m

Sep 30 2022n/an/a

US$154m

Jun 30 2022n/an/a

-US$106m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$2mUS$433k

-US$173m

Sep 30 2021n/an/a

-US$145m

Jun 30 2021n/an/a

-US$138m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$960kUS$420k

-US$44m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$105m

Dec 31 2019US$1mUS$292k

-US$113m

보상 대 시장: Mike 의 총 보상 ($USD 1.31M )은 US 시장( $USD 647.72K ).

보상과 수익: Mike 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Mike Andriole (51 yo)

1.3yrs

테뉴어

US$1,312,421

보상

Mr. Michael T. Andriole, also known as Mike, is CEO, President & Director of Chimerix, Inc. since August 01, 2023 and had been the Chief Business Officer of Chimerix, Inc. since April 8, 2019 until August...


리더십 팀

이름위치테뉴어보상소유권
Michael Andriole
CEO, President & Director1.3yrsUS$1.31m0.37%
$ 303.6k
Michael Alrutz
Senior VP10.2yrsUS$793.85k0.15%
$ 119.9k
Allen Melemed
Chief Medical Officer4.4yrsUS$931.79k0.062%
$ 50.1k
Michelle LaSpaluto
Chief Financial Officerless than a year데이터 없음0.12%
$ 100.4k
Thomas Riga
Chief Operating & Commercial Officerless than a year데이터 없음데이터 없음
David Jakeman
Vice President of Accounting & Finance5.4yrs데이터 없음0.12%
$ 99.4k
Joshua Allen
Chief Scientific Officerless than a year데이터 없음데이터 없음
Roy Ware
Chief Manufacturing Technology Officer1.1yrs데이터 없음데이터 없음

1.2yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: CMRX 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Michael Andriole
CEO, President & Director1.3yrsUS$1.31m0.37%
$ 303.6k
Fred Middleton
Independent Director6.7yrsUS$119.52k0.34%
$ 278.0k
Seth Rudnick
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Martha Demski
Lead Independent Director19.8yrsUS$144.52k0.080%
$ 65.1k
Michael Sherman
Chairman5.6yrsUS$1.52m0.39%
$ 319.8k
Douglas Richman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Pratik Multani
Independent Director4.8yrsUS$104.52k0%
$ 0
Michael Boeckh
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Earl Kern
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Raymund Razonable
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Robert Meyer
Independent Director6.7yrsUS$117.02k0.039%
$ 31.8k
Victoria Vakiener
Independent Director3.6yrsUS$107.02k0%
$ 0

5.6yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: CMRX 의 이사회경험(평균 재직 기간 5.6 년)으로 간주됩니다.